First- or Second- Class Compression Hosiery After Endovenous Laser With Sclerotherapy and Ambulatory Phlebectomy
Launched by MOSCOW CITY HOSPITAL NAMED AFTER A.K. ERAMISHANTSEV · Mar 31, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different levels of compression hosiery can help patients after a specific vein treatment. The researchers want to see if using first-class compression stockings, which are easier to put on and more comfortable, will help patients stick to their treatment plan better than second-class stockings. The trial involves patients who have varicose veins in their legs and are receiving a procedure called endovenous laser ablation, along with sclerotherapy and phlebectomy, to treat these veins.
To be eligible for this study, participants must be at least 18 years old and have varicose veins classified as C2-C5, which means they have noticeable symptoms but not severe complications. They should be undergoing the recommended vein treatment and must have given their consent to join the study. Patients who have a history of certain vein problems or other specific medical conditions may not be able to participate. Those who join the study can expect to wear either first-class or second-class compression stockings for two weeks after their procedure, and the researchers will monitor how well these stockings work for them.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Varicose veins of the lower extremities (CEAP classification C2-C5)
- • Varicose disease in the great saphenous vein (GSV) and its tributaries
- • Planned endovenous laser ablation of the GSV trunk with concomitant combined sclerotherapy and phlebectomy of tributaries
- • Technical success of intervention (complete ablation of the GSV)
- • Signed informed consent for study participation
- Exclusion Criteria:
- • Primary reflux outside the GSV trunk
- • History of or acute deep vein thrombosis
- • Deep vein insufficiency
- • GSV recanalization post-intervention
- • Clinical class C6 of chronic venous disease (CVD) according to CEAP classification
- • Contraindications or limitations for prolonged compression therapy, including but not limited to chronic arterial diseases of the lower extremities (any severity), skin diseases
- • Pathological conditions of lower limbs causing non-venous pain
- • Use of vasoactive medications within 1 month before/after surgery
- • Refusal to participate in the study
About Moscow City Hospital Named After A.K. Eramishantsev
Moscow City Hospital named after A.K. Eramishantsev is a leading healthcare institution dedicated to advancing medical research and patient care. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies that contribute to the development of new therapies and improve treatment outcomes. With a team of experienced medical professionals and researchers, the hospital fosters a collaborative environment to ensure high standards of ethics, safety, and scientific rigor in all clinical trials. Its strategic location in Moscow allows for diverse patient recruitment and engagement, further enhancing the impact of its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Moscow, , Russian Federation
Patients applied
Trial Officials
Hovsep P. Manjikian, MD
Study Chair
Moscow City Hospital named after A.K. Eramishantsev
Boris Danelian, MD
Principal Investigator
Moscow City Hospital named after A.K. Eramishantsev
Hovsep Manjikyan, MD
Principal Investigator
Moscow City Hospital named after A.K. Eramishantsev
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported